Get started
Work

140P Preliminary safety and efficacy of ixotatug vedotin (TORL-1-23), a Claudin 6-targeted ADC, in combination with bevacizumab in recurrent ovarian cancer

Year: 2026
Type: article
Abstract: Claudin-6 (CLDN6) is a cell surface protein and member of the claudin family of tight junction molecules expressed at high levels in multiple human cancers including high-grade serous ovarian cancer, with little or no expression in normal adult tissues. CLDN6 overexpression is associated with worse progression-free survival and overall survival in ovarian cancer. Ixotatug vedotin (Ixo-V) is a first-in-class IgG1-vc-MMAE antibody drug conjugate that specifically targets CLDN6 positive (CLDN6+) disease.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.108187
Authors: J-Y. Lee, G.M. Kim, A.E. Wahner Hendrickson, H. Pulaski, B. Keam, B. Shim, D. Slamon, G.E. Konecny
Institutions: Yonsei University, Yonsei University Health System, Mayo Clinic, Texas Oncology, Seoul National University, Seoul National University Hospital, The Catholic University of Korea St. Vincent's Hospital, Catholic University of Korea, University of California, Los Angeles
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167083381
FWCI:
Cites:
Cited by:
Related to: